Sign In
Buy MRK
$115.17
+0.270 (+0.235%)
At Close: Jun 16, 2026
Many pharma companies already made U.S. investment promises, says Citi's Geoff Meacham
04:50pm, Friday, 26'th Sep 2025
CNBC's “Closing Bell Overtime” team discusses President Trump's plan to impose a 100% tariff on “all any branded or patented Pharmaceutical Product” entering the U.S. with Geoff Meacham of Cit
Big Pharma braces for the next price cut
12:11pm, Friday, 26'th Sep 2025
Drugmakers know the script by now. Washington picks a handful of blockbuster medicines, haggles with their makers, and then publishes the “maximum fair price” that Medicare will pay.
Merck: Game-Changing Oncology Drugs Power Stock Surge
11:46am, Friday, 26'th Sep 2025
Despite the challenges Merck's vaccine franchise has faced, demand for its anti-cancer medications remains as high as ever. Welireg sales reached $162 million in Q2 2025, an increase of 18.2% quarter-
MRK vs. BMY: Which Pharma Stock Is the Smarter Pick Now?
10:41am, Friday, 26'th Sep 2025
Merck and Bristol Myers face diverging growth paths, with Keytruda driving MRK's momentum and BMY navigating generic headwinds.
Goldman Sachs Sees 4 Rate Cuts by Next Summer: 5 High-Yield Dividend Winners
10:11am, Friday, 26'th Sep 2025
Investors love dividend stocks because they offer a significant income stream and have massive total return potential.
Merck: 25% Total Return CAGR Potential
10:54am, Thursday, 25'th Sep 2025
Merck & Co. is rated a Strong Buy at $79.89, offering robust growth, a 4% yield, and significant undervaluation. MRK's pipeline, led by Keytruda derivatives and new blockbusters from acquisitions like
Here's Why Merck (MRK) is a Strong Value Stock
10:41am, Thursday, 25'th Sep 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
JP Morgan Says Economy Slowing Fast: 5 High-Yield Value Stock Fall Buys
04:13pm, Wednesday, 24'th Sep 2025
A value stock is generally a company that trades at a price lower than its fundamental value or what its performance suggests it should be worth.
Merck's Keytruda gets an upgrade
01:19pm, Wednesday, 24'th Sep 2025
CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest news.
Merck CEO Rob Davis on FDA approval of Keytruda injection, navigating new vaccine landscape
09:13am, Wednesday, 24'th Sep 2025
CNBC's Angelica Peebles and Merck chairman and CEO Rob Davis join 'Squawk Box' to discuss the FDA's approval of the injectable version of Keytruda, pricing for the new injection, navigating the new va
The Smartest Dividend Stock to Buy With $1,000 Right Now
07:45am, Wednesday, 24'th Sep 2025
The winds of political change have hit the healthcare industry, with drug makers seemingly taking the brunt of the gale. Industry-leading companies like Pfizer (PFE 0.33%), Merck (MRK -0.63%), and Bri
Variational AI Enters Collaboration with Merck to Apply Generative AI to Drug Discovery
07:00am, Tuesday, 23'rd Sep 2025
VANCOUVER, British Columbia--(BUSINESS WIRE)-- #AIDD--Variational AI enters Collaboration with Merck to apply Generative AI Drug Discovery platform to design and optimize novel small molecule therapeu
Merck (MRK) Stock Sinks As Market Gains: Here's Why
06:51pm, Monday, 22'nd Sep 2025
The latest trading day saw Merck (MRK) settling at $80.4, representing a -1.36% change from its previous close.
Will the FDA's Nod for Subcutaneous Keytruda Ease Merck's Headwinds?
11:26am, Monday, 22'nd Sep 2025
FDA clears MRK's Keytruda Qlex, a subcutaneous option that promises faster treatment and new patent protection amid looming headwinds.
3 Dirt-Cheap Stocks to Buy Right Now
08:30am, Monday, 22'nd Sep 2025
The major market indexes are bumping against all-time highs. It's not surprising, therefore, that many stocks are trading at steep valuations.
